SCHEMBL3405236

SCHEMBL3405236

CCn1c(-c2cccc3ccccc23)nc(C(=O)C2CCN(C3CCC3)CC2)c1[Si](C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.41
KDM2B Q8NHM5 4/20 0.38
HTR2C P28335 3/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HTR6 P50406 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
OGFRL1 Q5TC84 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
OPRL1 P41146 1/20 0.35
APOBEC3A P31941 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
MAPK1 P28482 1/20 0.35
KCNH2 Q12809 2/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3401099 0.81 GAA (0.43) GAAKDM2BHTR2CMEN1KMT2A
SCHEMBL3401298 0.78 HTR2C (0.46) HTR2CMEN1KMT2AKDM4EALDH1A1
SCHEMBL3404715 0.78 GAA (0.46) GAAKDM2BHTR2CKDM4EALDH1A1
SCHEMBL3401027 0.76 HTR2C (0.46) HTR2CMEN1KMT2AKDM4EALDH1A1
SCHEMBL3401043 0.74 HTR2C (0.56) HTR2CMEN1KMT2AKDM4EALDH1A1
SCHEMBL3399744 0.73 HTR2C (0.47) HTR2CMEN1KMT2AKDM4EALDH1A1
SCHEMBL3402170 0.73 HTR2C (0.47) HTR2CMEN1KMT2AKDM4EALDH1A1
SCHEMBL3405387 0.72 HTR2C (0.56) HTR2CMEN1KMT2AKDM4EALDH1A1
SCHEMBL3402312 0.72 HTR2C (0.43) HTR2CMEN1KMT2AKDM4EALDH1A1
SCHEMBL3404758 0.71 HTR2C (0.47) HTR2CMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
EP-1848428-A2 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-10-31 EP disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed
WO-2006089076-A2 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 GAA 1659/4885KDM2B 3049/4885HTR2C 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.